Nociceptin / Orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases

Current Drug Targets

Volumn 14, Issue 10, 2013, Pages 1203-1209

  Sobczak, Marta ^a   Sałaga, Maciej ^a   Storr, Martin ^b   Fichna, Jakub ^a,c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MUNICH   (Germany)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Abdominal pain; Gastrointestinal transit; Inflammatory bowel diseases; Irritable bowel syndrome; Nociceptin; Nociceptin Orphanin FQ receptor

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1, 3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; CXCL1 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NOCICEPTIN; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR AGONIST; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; COLITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; INFLAMMATION; INFLAMMATORY PAIN; IRRITABLE COLON; NEOPLASM; NEUTROPHIL; NONHUMAN; SEPSIS;

ANIMALS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS; OPIOID PEPTIDES; PAIN; RECEPTORS, OPIOID; SEPSIS;

EID: 84881331953     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990174     Document Type: Article

References (54)

1. Meunier JC, Mollereau C, Toll L, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-5.
2. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995; 270: 792-4.
3. Chen Y, Fan Y, Liu J, et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 1994; 347: 279-83.
4. Henderson G, McKnight AT. The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends Pharmacol Sci 1997; 18: 293-300.
5. Darland T, Heinricher MM, Grandy DK. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998; 21: 215-21.
6. Osinski MA, Pampusch MS, Murtaugh MP, Brown DR. Cloning, expression and functional role of a nociceptin/orphanin FQ receptor in the porcine gastrointestinal tract. Eur J Pharmacol 1999; 365: 281-9.
7. Lutfy K, Maidment NT. Blockade of mu-opioid receptors reveals the hyperalgesic effect of orphanin FQ/nociceptin in the rat hot plate test. Br J Pharmacol 2000; 131: 1684-8.
8. Reinscheid RK, Nothacker H, Civelli O. The orphanin FQ/nociceptin gene: structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides 2000; 21: 901-6.
9. Alt C, Lam JS, Harrison MT, et al. Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis. Eur.J.Pharmacol 2012; 683: 285-93.
10. Broccardo M, Guerrini R, Petrella C, Improta G. Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphaninFQ in rats. Peptides 2004; 25: 1013-20.
11. Kato S, Tsuzuki Y, Hokari R, et al. Role of nociceptin/orphanin FQ (Noc/oFQ) in murine experimental colitis. J Neuroimmunol 2005; 161: 21-8.
12. Yuce B, Sibaev A, Haaken A, et al. ORL-1 receptor mediates the action of nociceptin on ascending myenteric reflex pathways in rats. Gastroenterology 2007; 133: 574-86.
13. Hara N, Minami T, Okuda-Ashitaka E, et al. Characterization of nociceptin hyperalgesia and allodynia in conscious mice. Br J Pharmacol 1997; 121: 401-8.
14. Minami T, Okuda-Ashitaka E, Mori H, et al. Characterization of nociceptin/orphanin FQ-induced pain responses in conscious mice: neonatal capsaicin treatment and N-methyl-D-aspartate receptor GluRepsilon subunit knockout mice. Neuroscience 2000; 97: 133-42.
15. Nozaki-Taguchi N, Yamamoto T. Spinal opioid receptor like1 receptor agonist, but not N-methyl-D-aspartic acid antagonist, reverses the secondary mechanical allodynia induced by intradermal injection of capsaicin in rats. Anesth Analg 2005; 100: 1087-92.
16. Chen LY, Huang JX, Yu LC. Involvement of ORL1 receptor and ERK kinase in the orphanin FQ-induced nociception in the nucleus accumbens of rats. Regul Pept 2008; 151: 43-7.
17. Himukashi S, Takeshima H, Koyanagi S, Shichino T, Fukuda K. The involvement of the nociceptin receptor in the antinociceptive action of nitrous oxide. Anesth Analg 2006, 103: 738-41.
18. Fiset ME, Gilbert C, Poubelle PE, Pouliot M. Human neutrophils as a source of nociceptin: a novel link between pain and inflammation. Biochemistry 2003; 42: 10498-505.
19. Arjomand J, Cole S, Evans CJ. Novel orphanin FQ/nociceptin transcripts are expressed in human immune cells. J Neuroimmunol 2002; 130: 100-8.
20. Kaminsky DE, Rogers TJ. Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes. J Neuroimmune Pharmacol 2008; 3:75-82.
21. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000; 21: 907-17.
22. Halford WP, Gebhardt BM, Carr DJ. Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J Neuroimmunol 1995; 59: 91-101.
23. Miller TR, Fulford AJ. Regulation of nociceptin/orphaninFQ secretion by immune cells and functional modulation of interleukin-2. Peptides 2007; 28: 2243-52.
24. Serrano-Gomez A, Thompson JP, Lambert DG. Nociceptin/ orphanin FQ in inflammation and sepsis. Br J Anaesth 2011; 106: 6-12.
25. Serhan CN, Fierro IM, Chiang N, Pouliot M. Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J Immunol 2001; 166: 3650-4.
26. Trombella S, Vergura R, Falzarano S, et al. Nociceptin/orphanin FQ stimulates human monocyte chemotaxis via NOP receptor activation. Peptides 2005; 26: 1497-502.
27. Waits PS, Purcell WM, Fulford AJ, McLeod JD. Nociceptin/ orphanin FQ modulates human T cell function in vitro. J Neuroimmunol 2004; 149: 110-20.
28. Easten KH, Harry RA, Purcell WM, McLeod JD. Nociceptininduced modulation of human T cell function. Peptides 2009; 30: 926-34.
29. Hao JX, Xu IS, Wiesenfeld-Hallin Z, Xu XJ. Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain 1998; 76: 385-93.
30. Hom JS, Goldberg I, Mathis J, et al. [(125)I]orphanin FQ/nociceptin binding in Raji cells. Synapse 1999; 34: 187-91.
31. Carpenter KJ, Vithlani M, Dickenson AH. Unaltered peripheral excitatory actions of nociceptin contrast with enhanced spinal inhibitory effects after carrageenan inflammation: an electrophysiological study in the rat. Pain 2000; 85: 433-41.
32. Scoto GM, Arico G, Ronsisvalle S, Parenti C. Effects of intraplantar nocistatin and (+/-)-J 113397 injections on nociceptive behavior in a rat model of inflammation. Pharmacol Biochem Behav 2012; 100: 639-44.
33. Chen Y, Sommer C. Activation of the nociceptin opioid system in rat sensory neurons produces antinociceptive effects in inflammatory pain: involvement of inflammatory mediators. J Neurosci Res 2007; 85: 1478-88.
34. Fu X, Wang YQ, Wang J, Yu J, Wu GC. Changes in expression of nociceptin/orphanin FQ and its receptor in spinal dorsal horn during electroacupuncture treatment for peripheral inflammatory pain in rats. Peptides 2007; 28: 1220-8.
35. Agostini S, Eutamene H, Broccardo M, et al. Peripheral antinociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain 2009; 141: 292-99.
36. Carvalho D, Petronilho F, Vuolo F, et al. The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis. Intensive Care Med 2008; 34: 2284-90.
37. Goldfarb Y, Reinscheid RK, Kusnecov AW. Orphanin FQ/nociceptin interactions with the immune system in vivo: gene expression changes in lymphoid organs and regulation of the cyto kine response to staphylococcal enterotoxin A J Neuroimmunol 2006; 176: 76-85.
38. Stamer UM, Book M, Comos C, et al. Expression of the nociceptin precursor and nociceptin receptor is modulated in cancer and septic patients. Br J Anaesth 2011; 106: 566-72.
39. Osinski MA, Brown DR. Orphanin FQ/nociceptin: a novel neuromodulator of gastrointestinal function? Peptides 2000; 21: 999-1005.
40. Sugimori S, Kadowaki M, Yoneda S, et al. Nociceptin inhibits capsaicin-sensitive contraction to mesenteric nerve stimulation in the guinea-pig isolated ileum. Auton Neurosci 2000; 86: 65-9.
41. Ishihara S, Minowa S, Tsuchiya S, et al. Gastric acid secretion stimulated by centrally injected nociceptin in urethane-anesthetized rats. Eur J Pharmacol 2002; 441: 105-14.
42. Osinski MA, Bass P, Gaumnitz EA. Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am J Physiol 1999; 276: G125-G131.
43. Broccardo M, Guerrini R, Morini G, et al. The gastric effects of UFP-112, a new nociceptin/orphanin receptor agonist, in physiological and pathological conditions. Peptides 2007; 28: 1974-81.
44. Grandi D, Solenghi E, Guerrini R, et al. Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery. Peptides 2007; 28: 1572-9.
45. Grandi D, Solenghi E, Massi M, Morini G. Peripheral infusion of nociceptin/orphanin FQ influences the response of rat gastric and colonic mucosa to repeated stress. Regul Pept 2010; 160: 49-56.
46. Takahashi T, Mizuta Y, Owyang C. Orphanin FQ, but not dynorphin A, accelerates colonic transit in rats. Gastroenterology 2000; 119: 71-9.
47. Li HY, Yan X, Xue QL, et al. Effects of nociceptin/orphanin FQ on rats with cathartic colon. World J Gastroenterol 2007; 13: 141-5.
48. Broccardo M, Agostini S, Petrella C, Guerrini R, Improta G. Central and peripheral role of the nociceptin/orphaninFQ system on normal and disturbed colonic motor function and faecal pellet output in the rat. Neurogastroenterol Motil 2008; 20: 939-48.
49. Petrella C, Giuli C, Broccardo M, et al. Protective and worsening peripheral nociceptin/orphanin FQ receptor-mediated effect in a rat model of experimental colitis. Pharmacol Res 2013; 70: 72-9.
50. Mustazza C, Borioni A, Sestili I, et al. Synthesis and evaluation as NOP ligands of some spiro[piperidine-4,2'(1'H)-quinazolin]-4'(3'H)-ones and spiro[piperidine-4,5'(6'H)-[1,2,4]triazolo[1,5-c]quinazolines]. Chem.Pharm.Bull 2006; 54: 611-22.
51. Mustazza C, Bastanzio G. Development of nociceptin receptor (NOP) agonists and antagonists. Med Res Rev 2011; 31: 605-48.
52. Largent-Milnes TM, Vanderah TW. Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat 2010; 20: 291-305.
53. Przydzial MJ, Heisler LK. Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity. Mini Rev Med Chem 2008; 8: 796-811.
54. Matsushita H, Ishihara A, Mashiko S, et al. Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice. Endocrinology 2009; 150: 2668-73.